Last week, the AIDS Healthcare Foundation (AHF), a Los Angeles-based advocacy and treatment organization, sent a letter to Bristol-Myers Squibb (BMS) officials, pressing them to reduce the price of their AIDS drug Reyataz (atazanavir).

In its letter to BMS, AHF urged that AIDS Drug Assistance Programs (ADAPs) nationwide should receive the drug at a price similar to prices of first-line antiretroviral drugs like Viread (tenofovir) and Sustiva (efavirenz).

ADAPs throughout the United States aim to provide AIDS drugs like Reyataz to low-income people in need. This aim, however, is becoming…

The AIDS Healthcare Foundation (AHF), a Los Angeles based advocacy and treatment organization, continues to express concern over the high pricing for Merck’s anti-HIV drug, Isentress (raltegravir).

Isentress is an antiretroviral drug in the class known as integrase inhibitors. It was first approved by the United States Food and Drug Administration (FDA) in October 2007 for use in patients resistant to other HIV drugs, which is known as salvage therapy.

In July 2009, Isentress received FDA approval for use as first-line treatment, meaning that physicians can prescribe it for newly…